Somerset Indus Fund III Closes
Analysis based on 8 articles · First reported Mar 23, 2026 · Last updated Mar 24, 2026
The successful oversubscribed close of Fund III by Somerset Indus Capital Partners signals strong investor confidence in India's healthcare sector, particularly in underserved markets. This influx of capital is expected to drive growth and innovation in healthcare delivery, pharmaceuticals, and medical devices across India, potentially boosting related publicly traded companies and attracting further investment.
Somerset Indus Capital Partners, a Mumbai-headquartered private equity firm, announced the final close of its third fund, Fund III, at approximately $288 million, surpassing its initial target of $250 million. The fund attracted significant participation from global institutional investors, including Development Finance Institutions, global investment firms, and family offices across Europe, the United States, and Southeast Asia. Fund III will focus on improving healthcare access in India's Tier II and Tier III cities, investing in scalable businesses across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied sectors. Early investments from Fund III include Cyrix Healthcare, Printmann Offset, and NU Hospitals. Partners Avinash Kenkare and Mayur Sirdesai highlighted the strong endorsement of their strategy and commitment to combining financial performance with social impact.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard